Page 61 - Read Online

Berardi et al. J Cancer Metastasis Treat 2019;5:79 I http://dx.doi.org/10.20517/2394-4722.2019.008 Page 29 of 33

cancer metastasis. Clin Cancer Res 2005;11:5381-9.
11. Sanchez-Sandoval AL, Gomora JC. Contribution of voltage-gated sodium channel β-subunits to cervical cancer cells metastatic behavior.
Cancer Cell Int 2019;19:35.
12. Diss JK, Stewart D, Pani F, Foster CS, Walker MM, et al. A potential novel marker for human prostate cancer: voltage-gated sodium
channel expression in vivo. Prostate Cancer Prostatic Dis 2005;8:266-73.
13. Campbell TM, Main MJ, Fitzgerald EM. Functional expression of the voltage-gated Na -channel Nav1.7 is necessary for EGF-mediated
+
invasion in human non-small cell lung cancer cells. J Cell Sci 2013;126:4939-49.
14. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, et al. Voltage-gated Na channel SCN5A is a key regulator of a gene
+
transcriptional network that controls colon cancer invasion. Cancer Res 2010;70:6957-67.
15. Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, et al. Voltage-gated sodium channel polymorphisms play a
pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer
2013;119:3570-7.
16. Otterbach F, Callies R, Adamzik M, Kimmig R, Siffert W, et al. Aquaporin 1 (AQP1) expression is a novel characteristic feature of a
particularly aggressive subgroup of basal-like breast carcinomas. Breast Cancer Res Treat 2010;120:67-76.
17. Moon C, Soria JC, Jang SJ, Lee J, Obaidul Hoque M, et al. Involvement of aquaporins in colorectal carcinogenesis. Oncogene
2003;22:6699-703.
18. Wang P, Zhang C, Yu P, Tang B, Liu T, et al. Regulation of colon cancer cell migration and invasion by CLIC1-mediated RVD. Mol Cell
Biochem 2012;365:313-21.
19. Li A, Lu D, Zhang Y, Li J, Fang Y, et al. Critical role of aquaporin-3 in epidermal growth factor-induced migration of colorectal
carcinoma cells and its clinical significance. Oncol Rep 2013;29:535-40.
20. Dou R, Deng Y, Huang L, Fu S, Tan S, et al. Multi-microarray identifies lower AQP9 expression in adjuvant chemotherapy nonresponders
with stage III colorectal cancer. Cancer Lett 2013;336:106-13.
21. Liu S, Zhang S, Jiang H, Yang Y, Jiang Y. Co-expression of AQP3 and AQP5 in esophageal squamous cell carcinoma correlates with
aggressive tumor progression and poor prognosis. Med Oncol 2013;30:636.
22. Shen L, Zhu Z, Huang Y, Shu Y, Sun M, et al. Expression profile of multiple aquaporins in human gastric carcinoma and its clinical
significance. Biomed Pharmacother 2010;64:313-8.
23. Ayaz M, Karabagli H, Yanardag SB. Can hypo/hypernatremic conditions be a factor for Na ion channel kinetics: model study. Turk
Neurosurg 2018;28:421-7.
24. Ouwerkerk R, and Morgan RH. 23Na MRI: from research to clinical use. J Am Coll Radiol 2007;4:739-41.
25. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 2003;14:182-7.
26. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012;17:756-65.
27. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and
differential diagnosis. Support Care Cancer 2000;8:192-7.
28. Sengupta A, Banerjee SN, Biswas N M, Jash D, Saha K, et al. The incidence of hyponatraemia and its effect on the ECOG performance
status among lung cancer patients. J Clin Diagn Res 2013;7:1678-82.
29. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the subcommittee for the management of
lung cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990;61:597-604.
30. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, et al. The impact of low serum sodium on treatment outcome of targeted
therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol
2014;65:723-30.
31. Berardi R, Caramanti M, Fiordoliva I, Morgese F, Savini A, et al. Hyponatraemia is a predictor of clinical outcome for malignant pleural
mesothelioma. Support Care Cancer 2015;23:621-6.
32. Kim HS, Yi SY, Jun HJ, Lee J, Park JO, et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology
2007;73:192-7.
33. Choi JS, Bae EH, Ma SK, Kweon SS, Kim SW. Prognostic impact of hyponatraemia in patients with colorectal cancer. Colorectal Dis
2015;17:409-16.
34. Dhaliwal HS, Rohatiner AZ, Gregory W, Richards MA, Johnson PW, et al. Combination chemotherapy for intermediate and high grade
non-Hodgkin’s lymphoma. Br J Cancer 1993;68:767-74.
35. Jeppesen AN, Jensen HK, Donskov F, Marcussen N, von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic
renal cell carcinoma. Br J Cancer 2010;102:867-72.
36. Berardi R, Santoni M, Newsom-Davis T, Caramanti M, Rinaldi S, et al. Hyponatremia normalization as an independent prognostic factor
in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget 2017;8:23871-9.
37. Berardi R, Caramanti M, Castagnani M, Guglielmi S, Marcucci F, et al. Hyponatremia is a predictor of hospital length and cost of stay
and outcome in cancer patients. Support Care Cancer 2015;23:3095-101.
38. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert
panel recommendations. Am J Med 2013;126:S1-42.
39. Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J
Intern Med 1995;238:97-110.
40. Berardi R, Santoni M, Rinaldi S, Nunzi E, Smerilli A, et al. Risk of hyponatraemia in cancer patients treated with targeted therapies: a
systematic review and meta-analysis of clinical trials. PLoS One 2016;11:e0152079.